Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord-derived mesenchymal stem cells (Guangzhou Saliai Stem Cell Science and Technology)
- Development stage
- Unknown
- Lead developer
- Guangzhou Saliai Stem Cell Science and Technology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This human umbilical cord-derived mesenchymal stem cell (hUC-MSC) therapy is an allogeneic cell-based biologic being developed by Guangzhou Saliai Stem Cell Science and Technology for the treatment of neuromyelitis optica spectrum disorders (NMOSD). The therapy functions through MSC-driven immunomodulation and paracrine signaling, which aim to suppress the autoimmune response and provide neuroprotection to astrocytes and neurons within the central nervous system. It is currently being evaluated in a large-scale, multicenter, randomized, placebo-controlled clinical trial (hUC-MSC-NMOSD study) in China, targeting AQP4-IgG seropositive patients to assess its efficacy in reducing disease progression and improving motor function. Preclinical studies have demonstrated that these cells can alleviate NMOSD progression by reducing inflammatory infiltration and preserving critical neural cells.
- Other names
- UC-MSCs for neuromyelitis opticaUmbilical cord mesenchymal stem cells (NMOSD)hUC-MSC
Beyond the preview
Go deeper on umbilical cord-derived mesenchymal stem cells (Guangzhou Saliai Stem Cell Science and Technology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord-derived mesenchymal stem cells (Guangzhou Saliai Stem Cell Science and Technology).